Shopping Cart 0
Cart Subtotal
USD 0

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Scope

Which companies are the most active within the pipeline for cognitive impairment disorders?

Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Cognitive Impairment Disorders Report Coverage

2.2 Cognitive Impairment Associated With Schizophrenia (CIAS)-Overview

2.3 Dementia-Overview

2.4 Mild Cognitive Impairment-Overview

2.5 Alzheimer's Disease-Overview

3 Therapeutics Development

3.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

3.2 Dementia

3.3 Mild Cognitive Impairment

3.4 Alzheimer's Disease

4 Therapeutics Assessment

4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

4.2 Dementia

4.3 Mild Cognitive Impairment

4.4 Alzheimer's Disease

5 Companies Involved in Therapeutics Development

5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

5.2 Dementia

5.3 Mild Cognitive Impairment

5.4 Alzheimer's Disease

6 Dormant Projects

6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

6.2 Dementia

6.3 Mild Cognitive Impairment

6.4 Alzheimer's Disease

7 Discontinued Products

7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

7.2 Dementia

7.3 Mild Cognitive Impairment

7.4 Alzheimer's Disease

8 Product Development Milestones

8.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

8.2 Dementia

8.3 Mild Cognitive Impairment

8.4 Alzheimer's Disease

9 Appendix

9.1 Methodology

9.2 Coverage

9.3 Secondary Research

9.4 Primary Research

9.5 Expert Panel Validation

9.6 Contact Us

9.7 Disclaimer


List Of Figure

1.2 List of Figures

Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 3: Number of Products under Development for Dementia

Figure 4: Number of Products under Development by Companies, Dementia

Figure 5: Number of Products under Development by Universities/Institutes, Dementia

Figure 6: Number of Products under Development for Mild Cognitive Impairment

Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment

Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment

Figure 9: Number of Products under Development for Alzheimer's Disease

Figure 10: Number of Products under Development by Companies, Alzheimer's Disease

Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease

Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 20: Number of Products by Top 10 Targets, Dementia

Figure 21: Number of Products by Stage and Top 10 Targets, Dementia

Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia

Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia

Figure 24: Number of Products by Top 10 Routes of Administration, Dementia

Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia

Figure 26: Number of Products by Top 10 Molecule Types, Dementia

Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia

Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment

Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment

Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment

Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment

Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment

Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment

Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease

Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease

Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease

Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease

Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease

Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease


List Of Table

1.1 List of Tables

Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 4: Number of Products under Development for Dementia

Table 5: Number of Products under Development by Companies, Dementia

Table 6: Number of Products under Development by Universities/Institutes, Dementia

Table 7: Products under Development by Companies, Dementia

Table 8: Products under Development by Universities/Institutes, Dementia

Table 9: Number of Products under Development for Mild Cognitive Impairment

Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment

Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment

Table 12: Products under Development by Companies, Mild Cognitive Impairment

Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment

Table 14: Number of Products under Development for Alzheimer's Disease

Table 15: Number of Products under Development by Companies, Alzheimer's Disease

Table 16: Number of Products under Development by Universities/Institutes, Alzheimer's Disease

Table 17: Products under Development by Companies, Alzheimer's Disease

Table 18: Products under Development by Universities/Institutes, Alzheimer's Disease

Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 23: Number of Products by Stage and Target, Dementia

Table 24: Number of Products by Stage and Mechanism of Action, Dementia

Table 25: Number of Products by Stage and Route of Administration, Dementia

Table 26: Number of Products by Stage and Molecule Type, Dementia

Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment

Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment

Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment

Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment

Table 31: Number of Products by Stage and Target, Alzheimer's Disease

Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer's Disease

Table 33: Number of Products by Stage and Route of Administration, Alzheimer's Disease

Table 34: Number of Products by Stage and Molecule Type, Alzheimer's Disease

Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Astellas Pharma Inc

Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AstraZeneca Plc

Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Bristol-Myers Squibb Co

Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Cadent Therapeutics

Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Coronis NeuroSciences Ltd

Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Eli Lilly and Co

Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by F. Hoffmann-La Roche Ltd

Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by H. Lundbeck AS

Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Heptares Therapeutics Ltd

Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Intra-Cellular Therapies Inc

Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Iproteos SL

Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Pfizer Inc

Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Sage Therapeutics Inc

Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Saniona AB

Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Spherium Biomed SL

Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Takeda Pharmaceutical Co Ltd

Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Vanda Pharmaceuticals Inc

Table 52: Dementia-Pipeline by Acadia Pharmaceuticals Inc

Table 53: Dementia-Pipeline by Accera Inc

Table 54: Dementia-Pipeline by Acorda Therapeutics Inc

Table 55: Dementia-Pipeline by Actinogen Medical Ltd

Table 56: Dementia-Pipeline by Adamas Pharmaceuticals Inc

Table 57: Dementia-Pipeline by AgeneBio Inc

Table 58: Dementia-Pipeline by Alector LLC

Table 59: Dementia-Pipeline by Allergan Plc

Table 60: Dementia-Pipeline by Anavex Life Sciences Corp

Table 61: Dementia-Pipeline by Asceneuron SA

Table 62: Dementia-Pipeline by Axon Neuroscience SE

Table 63: Dementia-Pipeline by Axovant Sciences Ltd

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AB Science SA

AbbVie Inc

AC Immune SA

Acadia Pharmaceuticals Inc

Accera Inc

Acorda Therapeutics Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AFFiRiS AG

AgeneBio Inc

Alector LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma

ALSP Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Annexon Inc

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Aptevo Therapeutics Inc

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Asceneuron SA

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Avineuro Pharmaceuticals Inc

Avraham Pharmaceuticals Ltd

Axon Neuroscience SE

Axovant Sciences Ltd

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cadent Therapeutics

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Celon Pharma SA

CereSpir Inc

CHA Bio & Diostech Co Ltd

Clera Inc

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

Corium International Inc

Coronis NeuroSciences Ltd

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

Cypralis Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Dr. August Wolff GmbH & Co KG Arzneimittel

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Ensemble Therapeutics Corp

Epigen Biosciences Inc

Evotec AG

F. Hoffmann-La Roche Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

Genzyme Corp

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hemostemix Inc

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

ICB International Inc

Ichor Medical Systems Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

India Globalization Capital Inc

Insys Therapeutics Inc

IntelGenx Corp

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Iproteos SL

IRLAB Therapeutics AB

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kadmon Corp LLC

Karuna Pharmaceuticals Inc

Krenitsky Pharmaceuticals Inc

K-Stemcell Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MediPost Co Ltd

MEDRx Co Ltd

MEI Pharma Inc

Merck & Co Inc

Microlin Bio Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeoNeuro SAS

Neuraltus Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Neurimmune Holding AG

Neuro Bio Ltd

NeuroGenetic Pharmaceuticals Inc

Neuron Biopharma SA

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

Neuro-Sys SAS

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Octapharma AG

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Ovensa Inc

Oxstem Ltd

P2D Bioscience

Pacific Northwest Biotechnology LLC

Pain Therapeutics Inc

Peptron Inc

Pfizer Inc

Pharmasum Therapeutics AS

Pharmaxis Ltd

Pharnext SA

Phoenix Biotechnology Inc

Prana Biotechnology Ltd

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

ProQR Therapeutics NV

Proteome Sciences Plc

Proteostasis Therapeutics Inc

Sage Therapeutics Inc

Saniona AB

SBI Pharmaceuticals Co Ltd

Sinil Pharmaceutical Co Ltd

Spherium Biomed SL

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

TauRx Therapeutics Ltd

Theranexus SAS

Therapix Biosciences Ltd

Vanda Pharmaceuticals Inc

Vicore Pharma AB

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

WhanIn Pharmaceutical Co Ltd

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for cognitive impairment associated with schizophrenia (CIAS), dementia, mild cognitive impairment and Alzheimer's disease, and features dormant and discontinued products.

These disorders are associated with impairments in cognitive abilities such as learning, memory and perception. Due to the complex and highly sophisticated nature of the central nervous system (CNS), the pathophysiology of these disorders is not well understood and treatment options remain limited. Currently, marketed drugs act by slowing disease progression or treating symptoms.

Worldwide, the burden of cognitive impairment disorders will increase significantly in the coming decades due to aging populations. Consequently, there is a strong need to develop new therapies that effectively treat symptoms and target underlying mechanisms of disease.

Scope

Which companies are the most active within the pipeline for cognitive impairment disorders?

Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

READ MORE

Scope

1 Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Cognitive Impairment Disorders Report Coverage

2.2 Cognitive Impairment Associated With Schizophrenia (CIAS)-Overview

2.3 Dementia-Overview

2.4 Mild Cognitive Impairment-Overview

2.5 Alzheimer's Disease-Overview

3 Therapeutics Development

3.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

3.2 Dementia

3.3 Mild Cognitive Impairment

3.4 Alzheimer's Disease

4 Therapeutics Assessment

4.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

4.2 Dementia

4.3 Mild Cognitive Impairment

4.4 Alzheimer's Disease

5 Companies Involved in Therapeutics Development

5.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

5.2 Dementia

5.3 Mild Cognitive Impairment

5.4 Alzheimer's Disease

6 Dormant Projects

6.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

6.2 Dementia

6.3 Mild Cognitive Impairment

6.4 Alzheimer's Disease

7 Discontinued Products

7.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

7.2 Dementia

7.3 Mild Cognitive Impairment

7.4 Alzheimer's Disease

8 Product Development Milestones

8.1 Cognitive Impairment Associated With Schizophrenia (CIAS)

8.2 Dementia

8.3 Mild Cognitive Impairment

8.4 Alzheimer's Disease

9 Appendix

9.1 Methodology

9.2 Coverage

9.3 Secondary Research

9.4 Primary Research

9.5 Expert Panel Validation

9.6 Contact Us

9.7 Disclaimer


List Of Figure

1.2 List of Figures

Figure 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 3: Number of Products under Development for Dementia

Figure 4: Number of Products under Development by Companies, Dementia

Figure 5: Number of Products under Development by Universities/Institutes, Dementia

Figure 6: Number of Products under Development for Mild Cognitive Impairment

Figure 7: Number of Products under Development by Companies, Mild Cognitive Impairment

Figure 8: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment

Figure 9: Number of Products under Development for Alzheimer's Disease

Figure 10: Number of Products under Development by Companies, Alzheimer's Disease

Figure 11: Number of Products under Development by Universities/Institutes, Alzheimer's Disease

Figure 12: Number of Products by Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 13: Number of Products by Stage and Top 10 Targets, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 14: Number of Products by Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 15: Number of Products by Stage and Top 10 Mechanism of Actions, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 16: Number of Products by Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 17: Number of Products by Stage and Routes of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 18: Number of Products by Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 19: Number of Products by Stage and Molecule Types, Cognitive Impairment Associated With Schizophrenia (CIAS)

Figure 20: Number of Products by Top 10 Targets, Dementia

Figure 21: Number of Products by Stage and Top 10 Targets, Dementia

Figure 22: Number of Products by Top 10 Mechanism of Actions, Dementia

Figure 23: Number of Products by Stage and Top 10 Mechanism of Actions, Dementia

Figure 24: Number of Products by Top 10 Routes of Administration, Dementia

Figure 25: Number of Products by Stage and Top 10 Routes of Administration, Dementia

Figure 26: Number of Products by Top 10 Molecule Types, Dementia

Figure 27: Number of Products by Stage and Top 10 Molecule Types, Dementia

Figure 28: Number of Products by Top 10 Targets, Mild Cognitive Impairment

Figure 29: Number of Products by Stage and Top 10 Targets, Mild Cognitive Impairment

Figure 30: Number of Products by Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 31: Number of Products by Stage and Top 10 Mechanism of Actions, Mild Cognitive Impairment

Figure 32: Number of Products by Routes of Administration, Mild Cognitive Impairment

Figure 33: Number of Products by Stage and Routes of Administration, Mild Cognitive Impairment

Figure 34: Number of Products by Molecule Types, Mild Cognitive Impairment

Figure 35: Number of Products by Stage and Molecule Types, Mild Cognitive Impairment

Figure 36: Number of Products by Top 10 Targets, Alzheimer's Disease

Figure 37: Number of Products by Stage and Top 10 Targets, Alzheimer's Disease

Figure 38: Number of Products by Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 39: Number of Products by Stage and Top 10 Mechanism of Actions, Alzheimer's Disease

Figure 40: Number of Products by Top 10 Routes of Administration, Alzheimer's Disease

Figure 41: Number of Products by Stage and Top 10 Routes of Administration, Alzheimer's Disease

Figure 42: Number of Products by Top 10 Molecule Types, Alzheimer's Disease

Figure 43: Number of Products by Stage and Top 10 Molecule Types, Alzheimer's Disease


List Of Table

1.1 List of Tables

Table 1: Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 2: Number of Products under Development by Companies, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 3: Products under Development by Companies Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 4: Number of Products under Development for Dementia

Table 5: Number of Products under Development by Companies, Dementia

Table 6: Number of Products under Development by Universities/Institutes, Dementia

Table 7: Products under Development by Companies, Dementia

Table 8: Products under Development by Universities/Institutes, Dementia

Table 9: Number of Products under Development for Mild Cognitive Impairment

Table 10: Number of Products under Development by Companies, Mild Cognitive Impairment

Table 11: Number of Products under Development by Universities/Institutes, Mild Cognitive Impairment

Table 12: Products under Development by Companies, Mild Cognitive Impairment

Table 13: Products under Development by Universities/Institutes, Mild Cognitive Impairment

Table 14: Number of Products under Development for Alzheimer's Disease

Table 15: Number of Products under Development by Companies, Alzheimer's Disease

Table 16: Number of Products under Development by Universities/Institutes, Alzheimer's Disease

Table 17: Products under Development by Companies, Alzheimer's Disease

Table 18: Products under Development by Universities/Institutes, Alzheimer's Disease

Table 19: Number of Products by Stage and Target, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 20: Number of Products by Stage and Mechanism of Action, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 21: Number of Products by Stage and Route of Administration, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 22: Number of Products by Stage and Molecule Type, Cognitive Impairment Associated With Schizophrenia (CIAS)

Table 23: Number of Products by Stage and Target, Dementia

Table 24: Number of Products by Stage and Mechanism of Action, Dementia

Table 25: Number of Products by Stage and Route of Administration, Dementia

Table 26: Number of Products by Stage and Molecule Type, Dementia

Table 27: Number of Products by Stage and Target, Mild Cognitive Impairment

Table 28: Number of Products by Stage and Mechanism of Action, Mild Cognitive Impairment

Table 29: Number of Products by Stage and Route of Administration, Mild Cognitive Impairment

Table 30: Number of Products by Stage and Molecule Type, Mild Cognitive Impairment

Table 31: Number of Products by Stage and Target, Alzheimer's Disease

Table 32: Number of Products by Stage and Mechanism of Action, Alzheimer's Disease

Table 33: Number of Products by Stage and Route of Administration, Alzheimer's Disease

Table 34: Number of Products by Stage and Molecule Type, Alzheimer's Disease

Table 35: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Astellas Pharma Inc

Table 36: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by AstraZeneca Plc

Table 37: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Bristol-Myers Squibb Co

Table 38: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Cadent Therapeutics

Table 39: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Coronis NeuroSciences Ltd

Table 40: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Eli Lilly and Co

Table 41: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by F. Hoffmann-La Roche Ltd

Table 42: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by H. Lundbeck AS

Table 43: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Heptares Therapeutics Ltd

Table 44: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Intra-Cellular Therapies Inc

Table 45: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Iproteos SL

Table 46: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Pfizer Inc

Table 47: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Sage Therapeutics Inc

Table 48: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Saniona AB

Table 49: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Spherium Biomed SL

Table 50: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Takeda Pharmaceutical Co Ltd

Table 51: Cognitive Impairment Associated With Schizophrenia (CIAS)-Pipeline by Vanda Pharmaceuticals Inc

Table 52: Dementia-Pipeline by Acadia Pharmaceuticals Inc

Table 53: Dementia-Pipeline by Accera Inc

Table 54: Dementia-Pipeline by Acorda Therapeutics Inc

Table 55: Dementia-Pipeline by Actinogen Medical Ltd

Table 56: Dementia-Pipeline by Adamas Pharmaceuticals Inc

Table 57: Dementia-Pipeline by AgeneBio Inc

Table 58: Dementia-Pipeline by Alector LLC

Table 59: Dementia-Pipeline by Allergan Plc

Table 60: Dementia-Pipeline by Anavex Life Sciences Corp

Table 61: Dementia-Pipeline by Asceneuron SA

Table 62: Dementia-Pipeline by Axon Neuroscience SE

Table 63: Dementia-Pipeline by Axovant Sciences Ltd

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

AB Science SA

AbbVie Inc

AC Immune SA

Acadia Pharmaceuticals Inc

Accera Inc

Acorda Therapeutics Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

Adamas Pharmaceuticals Inc

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

AFFiRiS AG

AgeneBio Inc

Alector LLC

Allergan Plc

Allgenesis Biotherapeutics Inc

Allinky Biopharma

ALSP Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings Inc

Amgen Inc

Anavex Life Sciences Corp

Annexon Inc

Aphios Corp

Apodemus AB

Applied Research using OMIC Sciences SL

Aptevo Therapeutics Inc

Araclon Biotech SL

Archer Pharmaceuticals Inc

ArmaGen Inc

Asceneuron SA

Astellas Pharma Inc

AstraZeneca Plc

Aucta Pharmaceuticals LLC

Avineuro Pharmaceuticals Inc

Avraham Pharmaceuticals Ltd

Axon Neuroscience SE

Axovant Sciences Ltd

Axsome Therapeutics Inc

Axxam SpA

AZTherapies Inc

Beactica AB

Berg LLC

BioArctic AB

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Boehringer Ingelheim GmbH

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Bsim2

Cadent Therapeutics

Cantabio Pharmaceuticals Inc

Cardax Inc

Carna Biosciences Inc

Celon Pharma SA

CereSpir Inc

CHA Bio & Diostech Co Ltd

Clera Inc

Cognition Therapeutics Inc

Cognosci Inc

CohBar Inc

Connexios Life Sciences Pvt Ltd

ConSynance Therapeutics Inc

Corium International Inc

Coronis NeuroSciences Ltd

Cortice Biosciences Inc

Cotinga Pharmaceuticals Inc

Crossbeta Biosciences BV

Cypralis Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Daval International Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dongkook Pharmaceutical Co Ltd

Dr. August Wolff GmbH & Co KG Arzneimittel

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Endece LLC

Ensemble Therapeutics Corp

Epigen Biosciences Inc

Evotec AG

F. Hoffmann-La Roche Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

Genzyme Corp

GlaxoSmithKline Plc

GliaCure Inc

Glialogix Inc

Golden Biotechnology Corp

Grifols SA

H. Lundbeck AS

Hemostemix Inc

Heptares Therapeutics Ltd

HitGen LTD

Hyundai Pharmaceutical Co Ltd

ICB International Inc

Ichor Medical Systems Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Immungenetics AG

Immunwork Inc

Impel NeuroPharma Inc

India Globalization Capital Inc

Insys Therapeutics Inc

IntelGenx Corp

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

Iproteos SL

IRLAB Therapeutics AB

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Kadmon Corp LLC

Karuna Pharmaceuticals Inc

Krenitsky Pharmaceuticals Inc

K-Stemcell Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Ltd

Lupin Ltd

M3 Biotechnology Inc

ManRos Therapeutics

MedDay SA

Medesis Pharma SA

MedImmune LLC

MediPost Co Ltd

MEDRx Co Ltd

MEI Pharma Inc

Merck & Co Inc

Microlin Bio Inc

MindImmune Therapeutics Inc

Mitsubishi Tanabe Pharma Corp

ModGene Pharma LLC

Montisera Ltd

NAL Pharmaceuticals Ltd

Nanomerics Ltd

NeoNeuro SAS

Neuraltus Pharmaceuticals Inc

Neurim Pharmaceuticals Ltd

Neurimmune Holding AG

Neuro Bio Ltd

NeuroGenetic Pharmaceuticals Inc

Neuron Biopharma SA

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

Neuro-Sys SAS

Neurotez Inc

New World Laboratories Inc

NoNO Inc

Novartis AG

Nymox Pharmaceutical Corp

Octapharma AG

Oryzon Genomics SA

Otsuka Holdings Co Ltd

Ovensa Inc

Oxstem Ltd

P2D Bioscience

Pacific Northwest Biotechnology LLC

Pain Therapeutics Inc

Peptron Inc

Pfizer Inc

Pharmasum Therapeutics AS

Pharmaxis Ltd

Pharnext SA

Phoenix Biotechnology Inc

Prana Biotechnology Ltd

Prevacus Inc

Priavoid GmbH

Probiodrug AG

Progenra Inc

ProMIS Neurosciences Inc

ProQR Therapeutics NV

Proteome Sciences Plc

Proteostasis Therapeutics Inc

Sage Therapeutics Inc

Saniona AB

SBI Pharmaceuticals Co Ltd

Sinil Pharmaceutical Co Ltd

Spherium Biomed SL

Stemedica Cell Technologies Inc

Sumitomo Dainippon Pharma Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Co Ltd

TauRx Therapeutics Ltd

Theranexus SAS

Therapix Biosciences Ltd

Vanda Pharmaceuticals Inc

Vicore Pharma AB

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

WhanIn Pharmaceutical Co Ltd